US Patent 11,458,143: Viloxazine ADHD Treatment Claims, Patent Scope, Expiration, and Generic Risk

US Patent 11,458,143 is a Supernus Pharmaceuticals patent directed to treating attention-deficit/hyperactivity disorder with viloxazine or a pharmaceutically acceptable salt. Its principal commercial relevance is Qelbree, the extended-release viloxazine product approved by the FDA for ADHD.

The patent is a method-of-treatment patent rather than a composition-of-matter patent. It does not claim viloxazine itself, which is an older chemical entity. Its value depends on whether a competing product or treatment regimen practices the claimed ADHD method and whether the claims withstand validity challenges based on prior art, written description, enablement, obviousness, and claim construction.

The claims cover:

Viloxazine treatment for ADHD.
Daily doses from approximately 20 mg to 800 mg.
Narrower preferred ranges of 100-600 mg, 150-400 mg, and 150-300 mg.
Treatment of human children.
ADHD patients with specified psychiatric comorbidities.
An asserted improved adverse-effect profile.

What patent protects viloxazine treatment for ADHD?

US Patent 11,458,143 protects specified methods of administering viloxazine to patients with ADHD. The independent claim requires four core elements:

Claim element	Scope
Disease	Patient suffering from ADHD
Active ingredient	Viloxazine or a pharmaceutically acceptable salt
Administration	Administration to the patient
Amount	A therapeutically effective amount
Product form	Viloxazine administered in a formulation

Claim 1 is the broadest claim. It does not expressly require:

Extended-release delivery;
A particular release profile;
A particular dosing frequency;
A specific salt;
A specific age;
A specific formulation excipient;
A particular ADHD subtype; or
A named brand such as Qelbree.

The wording "in a formulation" is broad. It can encompass a pharmaceutical dosage form containing viloxazine, subject to the claim's other limitations and the specification's disclosure. The claim does not, on its face, require the formulation to be extended release.

The patent therefore differs from a formulation patent that claims particle size, excipient composition, capsule structure, release kinetics, or manufacturing parameters. A generic developer could potentially avoid a formulation claim while still facing infringement risk under the method claims if its product is labeled and marketed for ADHD treatment.

How do claims 1 through 9 differ?

Claim 1: broad ADHD treatment method

Claim 1 requires treatment of a patient suffering from ADHD with a therapeutically effective amount of viloxazine or its pharmaceutically acceptable salt.

The phrase "therapeutically effective amount" is a functional dosage limitation. It is likely interpreted in light of the specification, clinical data, and the dependent claims that specify numerical dose ranges.

The claim is broad enough to cover both pediatric and adult treatment unless another claim limitation narrows the patient population.

Claims 2 through 5: dose-range claims

The dose claims create nested ranges:

Claim	Daily dose
Claim 2	About 20-800 mg
Claim 3	About 100-600 mg
Claim 4	About 150-400 mg
Claim 5	150-300 mg

Claim 5 is the narrowest and most commercially important dose claim because the FDA-approved Qelbree dosing range is centered within the claimed ranges. FDA labeling provides pediatric and adult dosing instructions that include 100 mg, 200 mg, 300 mg, 400 mg, and higher daily doses depending on the patient population and titration schedule.[1]

The use of "about" in claims 2 through 4 gives the claims tolerance around the stated endpoints. The exact scope would depend on intrinsic evidence, prosecution history, and whether a court finds the term sufficiently definite in context. Claim 5 omits "about" and is therefore more numerically precise.

A competitor using a daily dose outside 20-800 mg could avoid literal infringement of claim 2, but could still fall within claim 1 if the dose is therapeutically effective. Claims 3-5 create additional positions for enforcement against products using common clinical doses.

Claim 6: improved adverse-effect profile

Claim 6 adds that the treatment "provides an improved adverse effect profile."

This limitation creates a potential enforcement and validity issue. The claim does not expressly identify:

The comparator treatment;
The adverse effects being improved;
The required degree of improvement;
Whether the improvement must be statistically significant;
Whether the improvement must be measured in clinical trials; or
Whether the improvement must be present across all treated patients.

A court may interpret the limitation through the specification and prosecution record. The patent holder would likely need evidence that the accused treatment produces the claimed improvement. The defendant could challenge the limitation as indefinite, insufficiently enabled, or unsupported by the specification, depending on the patent record.

Claims 7 through 9: patient subgroups and comorbidities

Claim 7 narrows the method to a human child. It directly tracks the pediatric ADHD market, which was central to Qelbree's initial FDA approval.

Claim 8 covers ADHD patients who also suffer from:

Anxiety;
Depression; or
Bipolar disorder.

Claim 9 covers ADHD patients with:

Obsessive-compulsive disorder;
Tourette's Syndrome; or
Post-traumatic stress disorder.

These claims may have strategic value because they address patient populations with treatment complexity and a potential need for non-stimulant therapy. They may also be more difficult to enforce in ordinary generic substitution cases because a pharmacy generally does not know which comorbidities an individual patient has. They become more relevant where the product label, promotional materials, clinical trials, or prescribing information expressly target those populations.

What is the patent expiration date for US 11,458,143?

US Patent 11,458,143 was issued on October 4, 2022. Public patent records identify Supernus Pharmaceuticals as the patent owner or assignee and associate the patent family with an early-2010s priority date directed to viloxazine treatment for ADHD.[2]

The ordinary statutory term is generally calculated from the earliest effective nonprovisional filing date, not from the issue date. Based on the publicly reported family priority information, the unadjusted expiration is generally reported as approximately November 2034. The exact enforceable expiration can differ because of:

Patent-term adjustment;
Patent-term extension;
Terminal disclaimers;
Corrected patent records;
Priority-chain analysis; or
Post-grant proceedings.

The issue date does not mean the patent expires 20 years later. The relevant commercial analysis must use the earliest effective nonprovisional filing date and the USPTO term calculation.

Event	Date
Patent issued	October 4, 2022
Patent number	US 11,458,143 B2
Patent owner/assignee	Supernus Pharmaceuticals
Principal product relevance	Qelbree, viloxazine extended-release
Reported unadjusted term endpoint	Approximately November 2034
Key qualification	Confirm USPTO patent-term adjustment and Orange Book listing data

What is the Orange Book status of Qelbree and US 11,458,143?

Qelbree is listed in the FDA Orange Book as a prescription product containing viloxazine hydrochloride in extended-release capsules. FDA approval occurred in April 2021 for pediatric ADHD and was later expanded to adults.[1]

The Orange Book is the principal FDA source for approved drug products, patent listings, and regulatory exclusivity. A listed patent can create a Hatch-Waxman certification issue for an abbreviated new drug application, but listing does not itself establish that every claim is valid or infringed.[3]

For Qelbree, the relevant regulatory protections include:

Protection	Commercial effect
New drug approval	Establishes the approved reference product
FDA marketing exclusivity	Delays certain ANDA approvals during the applicable period
Listed patents	Require patent certifications by ANDA applicants
Method-of-use claims	May support a Paragraph IV dispute or a section viii carve-out
Formulation claims	May create additional barriers to substitutable generic approval

The Orange Book use code associated with a method patent is important. If the listed use is ADHD treatment and an ANDA applicant seeks approval for the same use, the applicant may need to certify under Paragraph IV or carve out the protected indication under section viii of the Hatch-Waxman framework.[3]

When does Qelbree lose exclusivity?

Qelbree's market exclusivity has multiple layers.

FDA regulatory exclusivity

The initial pediatric approval was subject to FDA regulatory exclusivity associated with the new chemical entity pathway. The adult indication was later approved, but an expanded indication does not necessarily create a new five-year NCE period.

Regulatory exclusivity is separate from patent protection. Even after FDA exclusivity ends, listed patents can continue to delay or complicate generic approval.

Patent exclusivity

The principal patent exposure associated with US 11,458,143 extends into the mid-2030s based on the reported patent family term. Other Qelbree patents may have different expiration dates and may cover formulations, dosing, or additional methods.

A generic applicant may therefore face a staggered patent estate:

Patent category	Possible effect
ADHD method claims	Can cover prescribing and labeling
Dose claims	Can cover common daily dose ranges
Pediatric claims	Can cover the initial commercial population
Formulation claims	Can cover the marketed extended-release product
Manufacturing claims	Can increase supply-chain and process risk

Generic launch timing will depend on which patents are listed at the time of ANDA filing, the certifications made, litigation outcomes, settlements, and whether a court permits an at-risk launch.

How strong is the patent estate for viloxazine?

The estate is stronger as a layered commercial barrier than as a single broad patent.

Strengths

The claims cover the core clinical use of viloxazine for ADHD.
The dose ranges encompass commercially relevant dosing.
Pediatric treatment is expressly claimed.
The claims address common comorbid psychiatric conditions.
Method claims can remain relevant even if a competitor designs around a specific capsule or excipient composition.
The claims map closely to Qelbree's approved therapeutic use.

Vulnerabilities

Viloxazine was known before the ADHD indication, making the active ingredient itself unavailable for new composition-of-matter exclusivity.
Method claims may face obviousness challenges based on prior clinical or pharmacological disclosures.
The broad claim language may invite written-description and enablement challenges.
"Improved adverse effect profile" in claim 6 may create definiteness and proof-of-infringement questions.
A generic applicant may attempt a section viii carve-out for protected methods of use.
A court could construe "therapeutically effective amount" or "in a formulation" more narrowly than the patent owner seeks.

The commercial strength of US 11,458,143 depends heavily on the specification, prosecution history, cited prior art, continuation practice, and any terminal disclaimer. The issued claims alone do not establish a presumption that every viloxazine product infringes.

What generic entry risks exist for viloxazine?

A generic viloxazine developer would likely evaluate four launch paths.

Paragraph III certification

The applicant accepts the listed patent and agrees not to market until the patent expires. For a patent with a reported term into 2034, this would defer launch unless the patent is invalidated, disclaimed, or removed.

Paragraph IV certification

The applicant certifies that the patent is invalid, unenforceable, or not infringed. The patent owner may bring a patent-infringement action within 45 days, potentially triggering a statutory stay of FDA approval for up to 30 months under Hatch-Waxman.[3]

Section viii carve-out

The applicant removes a patented method from the proposed labeling while retaining approval for unpatented uses. This strategy is difficult where the patent claims the principal or only approved use, but it may be available where the label can omit particular patient subgroups or dosing instructions.

At-risk launch

The applicant launches before final resolution. This creates damages exposure, possible injunctive relief, and commercial disruption if the patent holder prevails.

The highest-risk scenario is a generic label that mirrors ADHD treatment, uses daily doses within 100-600 mg, and targets pediatric patients. Such a label would align closely with claims 1-5 and 7.

Which companies are challenging Qelbree patent rights?

The supplied claim set does not identify an ANDA applicant, Paragraph IV notice, district-court action, or settlement agreement. No specific challenger, litigation outcome, or licensee can be reliably assigned from the claims alone.

The relevant public sources for identifying challenges are:

FDA Paragraph IV patent-certification updates;
PACER and district-court docket records;
Delaware and New Jersey Hatch-Waxman filings;
Orange Book patent-listing updates;
ANDA litigation announcements;
SEC filings by Supernus; and
Patent Trial and Appeal Board records.

A patent challenge must be analyzed patent by patent. A Paragraph IV challenge to a formulation patent does not necessarily resolve the separate method claims in US 11,458,143.

Are biosimilars a risk to viloxazine?

No. Viloxazine is a small-molecule drug, not a biologic. The relevant competitors are ANDA-based generic products, not biosimilars under the Public Health Service Act.

Generic applicants must address Qelbree's listed patents and demonstrate pharmaceutical equivalence and bioequivalence under the Federal Food, Drug, and Cosmetic Act. Extended-release products may face additional bioequivalence and formulation-development requirements, but those requirements do not convert viloxazine into a biologic product.

What licensing and manufacturing barriers affect viloxazine?

The patent claims do not disclose a licensing agreement or manufacturing restriction. The most relevant barriers are likely to arise from:

Access to viloxazine hydrochloride active pharmaceutical ingredient;
Extended-release formulation development;
Dissolution and bioequivalence testing;
Stability and capsule-manufacturing controls;
Patent claims directed to formulation or release characteristics; and
Supplier qualification and commercial-scale production.

A generic manufacturer could avoid infringement of a process patent by using a different manufacturing route, but it cannot assume that a different process avoids method-of-treatment claims. Conversely, a manufacturer may be able to produce a non-infringing formulation while still creating infringement risk through the product label.

How does US 11,458,143 compare with formulation patents?

Issue	US 11,458,143	Formulation patent
Claim type	Method of treatment	Composition or dosage form
Core limitation	ADHD treatment with viloxazine	Specific formulation attributes
Product design-around	Potentially difficult if label retains ADHD use	Often possible through excipient or release changes
Label relevance	Very high	Moderate to high
Manufacturing relevance	Usually indirect	Often direct
Pediatric coverage	Expressly claimed in claim 7	Depends on claim language
Generic certification risk	Use-code and method claims	Product-specific patent listing

The method patent and formulation patents are complementary. A generic developer may design around one category and still face the other.

Key Takeaways

US 11,458,143 is a Supernus method-of-treatment patent covering viloxazine use for ADHD.
Claim 1 is broad and does not expressly require extended-release delivery.
Claims 2-5 cover daily doses from approximately 20 mg to 800 mg, with a narrow 150-300 mg range in claim 5.
Claim 7 specifically covers treatment of human children.
Claims 8 and 9 cover ADHD patients with specified psychiatric comorbidities.
Claim 6 introduces an improved-adverse-effect limitation that may raise claim-construction and proof issues.
The patent's reported unadjusted term extends to approximately November 2034, subject to USPTO term adjustments and other statutory records.
Qelbree faces generic risk through Paragraph III, Paragraph IV, section viii, and potential at-risk launch strategies.
Viloxazine is a small molecule, so biosimilar competition is not applicable.
The strongest commercial overlap is a generic extended-release viloxazine product labeled for ADHD at pediatric or adult doses within the claimed ranges.
The claims supplied do not establish a named Paragraph IV challenger, litigation outcome, or settlement agreement.

FAQs About US Patent 11,458,143 and Qelbree

Does US 11,458,143 cover Qelbree itself?

It covers methods of treating ADHD with viloxazine, including dose ranges and pediatric treatment. It is not a composition-of-matter claim to Qelbree or to viloxazine as a chemical compound.

Can a generic viloxazine product avoid infringement by using a different formulation?

Not necessarily. A different formulation may avoid a formulation patent, but a product labeled for ADHD treatment could still implicate the method claims in US 11,458,143.

Does claim 5 cover the standard Qelbree pediatric dose?

Claim 5 covers a daily dose from 150 mg to 300 mg. Qelbree dosing that falls within that range would align with the numerical limitation, subject to the other claim elements and applicable claim construction.

Are adult ADHD patients covered by the patent?

Yes. Claim 1 is not limited to children. Claim 7 narrows the method to human children, but the independent claim can cover adults if the other limitations are met.

Does the patent prevent off-label viloxazine use?

The patent may create infringement risk for a method falling within its claims, but patent scope and FDA labeling are separate issues. FDA approval does not determine whether a use infringes, and patent infringement does not determine whether an indication is FDA-approved.

References

U.S. Food and Drug Administration. (2024). Qelbree (viloxazine hydrochloride) prescribing information. FDA.
U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,458,143: Methods of treating attention deficit hyperactivity disorder. USPTO.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-001	Apr 2, 2021		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-002	Apr 2, 2021		RX	Yes	No	⤷ Start Trial	⤷ Start Trial				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Start Trial
Supernus Pharms	QELBREE	viloxazine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	211964-003	Apr 2, 2021		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2735934	⤷ Start Trial
European Patent Office	2341912	⤷ Start Trial
Spain	2459322	⤷ Start Trial
World Intellectual Property Organization (WIPO)	2010028207	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 11,458,143

Which drugs does patent 11,458,143 protect, and when does it expire?

Summary for Patent: 11,458,143